NovaQuest Capital Management

NovaQuest Capital Management, based in Raleigh, North Carolina, is a private equity firm that specializes in investments within the global healthcare sector. Founded in 2000, NovaQuest primarily focuses on structured finance investments in late-stage clinical and commercial biopharmaceutical products, collaborating closely with global companies to enhance the value of their product portfolios. The firm also invests in select private equity and other company securities, maintaining a consistent emphasis on late-stage clinical and commercialized products. Over its history, NovaQuest has invested more than $1 billion in the healthcare industry, leveraging an experienced team that has worked together for over 12 years. The firm's investment strategy, developed through years of experience, utilizes a tailored approach to meet the evolving needs of healthcare companies and their investors. NovaQuest manages several funds, including co-investment and direct lending funds, targeting various sectors such as pharmaceuticals, biotechnology, and life sciences.

Michael Bologna

Partner and Chief Investment Officer

John Bradley

Partner, Founder and COO

Dain Clare

Vice President

Jacob Comer

Partner

Tsuyoshi Harada

Principal

Robert Hester

CFO and Partner

Ryu Kobayashi

Principal and Mitsui Liason

Stephen Lesser

Principal

Sharon Lorek

Vice President

Daisuke Makino

Principal

Chris Mauney

Vice President

Bryan Mills

Chief Administrative Officer and Partner

Jarett Poll

Principal

Devin Rosenthal

Vice President

Ankur Shah

Senior Associate

Jonathan Tunnicliffe

Co-Founder and Partner

Jonathan Tunnicliffe

Chief Investment Officer

Ron Wooten

Senior Founding Partner

Ryan Wooten

Managing Director

Ronald Wooten

Co-Founder and Managing General Partner

Past deals in North Carolina

TARGAN

Series C in 2022
Applied Lifesciences & Systems, LLC is a bio-systems company based in Raleigh, North Carolina, established in 2011. The company specializes in developing automated solutions for the detection, targeting, and delivery of vaccines in the poultry, aquaculture, and livestock sectors. Its innovative vaccine delivery system aims to enhance current vaccination methods by ensuring that each chick receives an accurate and consistent vaccination. This precision not only boosts the natural immune response to diseases but also improves overall flock health, contributing to cleaner and healthier poultry. Applied Lifesciences & Systems is committed to advancing animal health and productivity through its cutting-edge technology.

Aceragen

Private Equity Round in 2021
Aceragen is a developer of therapeutic treatments intended for rare and ultra-rare diseases.

Pro-ficiency

Acquisition in 2021
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training, and compliance monitoring tools, and real-time data & predictive analytics.

Clinical Ink

Private Equity Round in 2018
Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions tailored for the clinical research sector, assisting sites, sponsors, and contract research organizations (CROs) in streamlining their processes. The company's primary offering, SureSource, is an electronic source platform designed to capture essential clinical trial data and documents directly at the research site. Additionally, Clinical Ink provides Lunexis ePRO+, which facilitates patient participation by allowing flexible engagement options, and CentrosHealth, a platform that keeps patients informed and compliant throughout their clinical trial experience. Founded in 2006, Clinical Ink operates its headquarters in Horsham, Pennsylvania, and has additional offices in Winston-Salem, Cary, Philadelphia, and Cambridge. The company aims to enhance clinical trial workflows and improve data quality through its innovative electronic source solutions.

Viamet Pharmaceuticals

Acquisition in 2018
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.